NCT00041314 2023-06-15
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
9 trialsNCT00041054 2016-12-07
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00052845 2016-07-01
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00026468 2013-07-24
Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis
University of Utah
Phase 2/3 Withdrawn
NCT00078910 2013-06-24
Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00037609 2012-10-24
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00072618 2011-10-20
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
Astellas Pharma Inc
Phase 1/2 Completed
NCT00085826 2011-10-20
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Astellas Pharma Inc
Phase 3 Completed
NCT00166426 2009-11-16
Exisulind Versus Placebo After Surgical Removal of the Prostate
Mayo Clinic
Phase 2 Completed